Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2394195 | 1.00 | MEN1 (1.00) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| SCHEMBL2394204 | 1.00 | MEN1 (1.00) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| Ammonia Solution, Strong SCHEMBL29580190 | 0.99 | MEN1 (0.98) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| SCHEMBL794085 | 0.85 | MEN1 (0.73) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| SCHEMBL1430608 | 0.85 | MEN1 (0.73) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| SCHEMBL20693802 | 0.84 | MEN1 (0.72) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| SCHEMBL838875 | 0.84 | MEN1 (0.72) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| SCHEMBL30545232 | 0.84 | MEN1 (0.72) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| SCHEMBL838874 | 0.84 | MEN1 (0.72) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| SCHEMBL9344811 | 0.81 | MEN1 (0.69) | MEN1ALOX15CYP2C19KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4509120-A2 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | Amylyx Pharmaceuticals Inc. (US) | 2025-02-19 | — | — | EP | claimed |
| US-12186330-B2 | Compositions for improving cell viability and methods of use thereof | Amylyx Pharmaceuticals Inc. (US) | 2025-01-07 | — | — | US | claimed |
| EP-4475953-A1 | NMDAR ANTAGONISTS PREVENT AGEING AND AGING-ASSOCIATED CONDITIONS AND DISEASES THROUGH INCREASING 20S PROTEASOME ACTIVITY | SAHIN, Fikret (TR) | 2024-12-18 | — | — | EP | claimed |
| CN-119095622-A | NMDAR antagonists prevent aging and aging-related conditions and diseases by increasing 20S proteasome activity | 菲克雷特·萨欣 | 2024-12-06 | — | — | CN | claimed |
| WO-2023154014-A1 | NMDAR ANTAGONISTS PREVENT AGEING AND AGING-ASSOCIATED CONDITIONS AND DISEASES THROUGH INCREASING 20S PROTEASOME ACTIVITY | SAHIN FIKRET (TR) | 2023-08-17 | — | — | WO | claimed |
| US-20220160733-A1 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | Amylyx Pharmaceuticals Inc. | 2022-05-26 | — | — | US | claimed |
| US-12637450-B2 | Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways | GLOBAL CANCER TECHNOLOGY INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20250275985-A1 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | AMYLYX PHARMACEUTICALS, INC. | 2025-09-04 | — | — | US | disclosed |
| US-12357635-B2 | Nanocarriers and their processing for diagnostics and therapeutics | RHODE ISLAND HOSPITAL (US) | 2025-07-15 | — | — | US | disclosed |
| EP-3774783-B1 | TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS | NEUROPORE THERAPIES INC (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250161238-A1 | NMDAR Antagonists Prevent Ageing and Aging-Associated Conditions and Diseases Through Increasing 20S Proteasome Activity | SAHIN FIKRET (TR) | 2025-05-22 | — | — | US | disclosed |
| EP-4509120-A2 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | Amylyx Pharmaceuticals Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| US-12186330-B2 | Compositions for improving cell viability and methods of use thereof | Amylyx Pharmaceuticals Inc. (US) | 2025-01-07 | — | — | US | disclosed |
| US-11345713-B2 | Compounds as modulators of TLR2 signaling | NEUROPORE THERAPIES, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220160733-A1 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | Amylyx Pharmaceuticals Inc. | 2022-05-26 | — | — | US | disclosed |
| US-20220110948-A1 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | AMYLYX PHARMACEUTICALS, INC. | 2022-04-14 | — | — | US | disclosed |
| US-11299487-B2 | Compounds and compositions as modulators of TLR signaling | NEUROPORE THERAPIES, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| WO-2022067114-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| EP-3946599-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | Neuropore Therapies, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-11236079-B2 | Morpholine derivates as inhibitors of Vps34 | NEUROPORE THERAPIES, INC. (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160733-A1 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | HSPA9, CYP27A1, TUFM | MEN1 4437/4885ALOX15 532/4885CYP2C19 2671/4885 |
| US-20250275985-A1 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | HSPA9, CYP27A1, TUFM | MEN1 4437/4885ALOX15 532/4885CYP2C19 2671/4885 |
| US-12357635-B2 | Nanocarriers and their processing for diagnostics and therapeutics | SYVN1, SSB, TNF | MEN1 3527/4885ALOX15 2293/4885CYP2C19 4627/4885 |
| US-12637450-B2 | Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways | PIK3R4, PIK3R1, ATG7 | MEN1 4728/4885ALOX15 3896/4885CYP2C19 3997/4885 |
| US-20220110948-A1 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | HSPA9, CYP27A1, TUFM | MEN1 4437/4885ALOX15 532/4885CYP2C19 2671/4885 |
| US-11345713-B2 | Compounds as modulators of TLR2 signaling | TLR2, TLR4, TLR3 | MEN1 4870/4885ALOX15 1657/4885CYP2C19 4881/4885 |
| US-12186330-B2 | Compositions for improving cell viability and methods of use thereof | HSPA9, CYP27A1, TUFM | MEN1 4437/4885ALOX15 532/4885CYP2C19 2671/4885 |
| US-11236079-B2 | Morpholine derivates as inhibitors of Vps34 | VPS35, TFEB, VPS4B | MEN1 3272/4885ALOX15 4813/4885CYP2C19 4843/4885 |
| US-11299487-B2 | Compounds and compositions as modulators of TLR signaling | TLR3, TLR6, TLR4 | MEN1 4878/4885ALOX15 1693/4885CYP2C19 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.